



Study Title:	Study adjuvant Ipilimumab versus high-dose interferon for resection, high-risk melanoma patients
Scientific Title:	E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
Department and/or Specialty:	Regional Cancer Center
Investigator:	Michael Thompson, MD, PhD
Contact Information:	Chanda Miller 262-928-5539
<ol style="list-style-type: none">1. To evaluate recurrence-free survival (RFS) between patients randomized to receive post-operative adjuvant ipilimumab versus those randomized to receive high-dose recombinant interferon alfa-2b(HDI).2. To evaluate overall survival (OS) between patients randomized to receive postoperative adjuvant ipilimumab versus those randomized to receive HDI.	

